CL2017000416A1 - Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos - Google Patents

Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos

Info

Publication number
CL2017000416A1
CL2017000416A1 CL2017000416A CL2017000416A CL2017000416A1 CL 2017000416 A1 CL2017000416 A1 CL 2017000416A1 CL 2017000416 A CL2017000416 A CL 2017000416A CL 2017000416 A CL2017000416 A CL 2017000416A CL 2017000416 A1 CL2017000416 A1 CL 2017000416A1
Authority
CL
Chile
Prior art keywords
methods
multiple myeloma
antibodies
combination
treating multiple
Prior art date
Application number
CL2017000416A
Other languages
English (en)
Spanish (es)
Inventor
Anjan Thakurta
Mohamed Hussein
Christian Jacques
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54035318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000416(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2017000416A1 publication Critical patent/CL2017000416A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CL2017000416A 2014-08-22 2017-02-20 Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos CL2017000416A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462040918P 2014-08-22 2014-08-22

Publications (1)

Publication Number Publication Date
CL2017000416A1 true CL2017000416A1 (es) 2017-09-08

Family

ID=54035318

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000416A CL2017000416A1 (es) 2014-08-22 2017-02-20 Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos

Country Status (24)

Country Link
US (1) US10034872B2 (enExample)
EP (2) EP3925609B1 (enExample)
JP (2) JP7120763B2 (enExample)
KR (1) KR20170042598A (enExample)
CN (1) CN107073115A (enExample)
AU (2) AU2015305449B2 (enExample)
BR (1) BR112017003620A2 (enExample)
CA (1) CA2958867A1 (enExample)
CL (1) CL2017000416A1 (enExample)
DK (1) DK3182996T3 (enExample)
EA (1) EA201790439A1 (enExample)
ES (2) ES2940302T3 (enExample)
FI (1) FI3182996T3 (enExample)
HR (1) HRP20230265T1 (enExample)
HU (1) HUE061382T2 (enExample)
IL (1) IL250724A0 (enExample)
LT (1) LT3182996T (enExample)
MX (1) MX388383B (enExample)
PL (1) PL3182996T3 (enExample)
PT (1) PT3182996T (enExample)
RS (1) RS64038B1 (enExample)
SI (1) SI3182996T1 (enExample)
SM (1) SMT202300081T1 (enExample)
WO (1) WO2016029004A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017027692A2 (pt) * 2015-06-29 2018-10-09 Bristol Myers Squibb Co regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do câncer
MX387646B (es) 2016-12-21 2025-03-18 Biotheryx Inc Derivados de tienopirrol para uso en seleccion como diana de proteínas, composiciones, métodos y usos de los mismos.
WO2019072220A1 (zh) * 2017-10-13 2019-04-18 江苏恒瑞医药股份有限公司 Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
DK3703750T3 (da) 2017-11-01 2025-02-10 Juno Therapeutics Inc Kimæriske antigenreceptorer, der er specifikke for b-cellemodningsantigen, og som koder for polynukleotider
US11191769B2 (en) * 2018-06-13 2021-12-07 Biotheryx, Inc. Fused thiophene compounds
AU2019351811B2 (en) * 2018-10-01 2025-01-02 Celgene Corporation Combination therapy for the treatment of cancer
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
TW202038975A (zh) * 2018-11-13 2020-11-01 美商南塞爾公司 多發性骨髓瘤之組合治療
AU2020228803B2 (en) * 2019-02-25 2023-05-18 Shanghaitech University Sulfur-containing compound based on glutarimide skeleton and application thereof
US20230028293A1 (en) * 2019-12-08 2023-01-26 The Regents Of The University Of Colorado, A Body Corporate Multiple myeloma combination therapies based on protein translation inhibitors and immunomodulators
WO2021118353A1 (en) * 2019-12-11 2021-06-17 Erasmus University Medical Center Rotterdam Method for monitoring of deep remissions in multiple myeloma and other plasma cell dyscrasias
WO2022072538A1 (en) * 2020-09-30 2022-04-07 Biotheryx, Inc. Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
JP2024529038A (ja) * 2021-08-04 2024-08-01 アイヴィス バイオ インコーポレーテッド 物質特性が改善された免疫調節アミド誘導体
KR102362871B1 (ko) * 2021-11-19 2022-02-15 케이블루바이오 주식회사 신규한 사환구조 트리테르펜 화합물을 유효성분으로 포함하는 다발성골수종의 예방 또는 치료용 조성물

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1164829B (de) 1961-04-26 1964-03-05 Bayer Ag Verfahren zur elektrophotographischen Herstellung von Bildern mit Fluessigkeitsaerosolen
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5974203A (en) 1988-04-11 1999-10-26 Canon Kabushiki Kaisha Pattern recognition communication apparatus for transmitting and receiving image data
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU8868891A (en) 1990-10-12 1992-05-20 Amgen, Inc. Megakaryocyte maturation factors
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
WO1992014455A1 (en) 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US20010056114A1 (en) 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US6114355A (en) 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5594637A (en) 1993-05-26 1997-01-14 Base Ten Systems, Inc. System and method for assessing medical risk
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5641758A (en) 1993-11-10 1997-06-24 Kluge; Michael Cytarabine derivatives, the preparation and use thereof
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
MX9702723A (es) 1994-10-28 1998-04-30 Advanced Health Med E Systems Sistema de administracion de recetas.
US5593696A (en) 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5619991A (en) 1995-04-26 1997-04-15 Lucent Technologies Inc. Delivery of medical services using electronic data communications
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
US5731325A (en) 1995-06-06 1998-03-24 Andrulis Pharmaceuticals Corp. Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
US5832449A (en) 1995-11-13 1998-11-03 Cunningham; David W. Method and system for dispensing, tracking and managing pharmaceutical trial products
US6063026A (en) 1995-12-07 2000-05-16 Carbon Based Corporation Medical diagnostic analysis system
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
KR20050032629A (ko) 1996-07-24 2005-04-07 셀진 코포레이션 치환된 2-(2,6-디옥소피페리딘-3-일)-프탈이미드와 치환된2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린과 ＴＮＦα농도를 감소시키는 방법
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
KR100539030B1 (ko) 1996-08-12 2005-12-27 셀진 코포레이션 면역치료제 및 이를 이용하여 사이토카인 농도를 감소시키는 방법
US5924074A (en) 1996-09-27 1999-07-13 Azron Incorporated Electronic medical records system
ATE493983T1 (de) 1996-11-05 2011-01-15 Childrens Medical Center Thalidomide und dexamethason für die behandlung von tumors
US6131090A (en) 1997-03-04 2000-10-10 Pitney Bowes Inc. Method and system for providing controlled access to information stored on a portable recording medium
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
PT998271E (pt) 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
AU8909898A (en) 1997-08-22 1999-03-16 Deka Products Limited Partnership Health care system and method for physician order entry
US5874448A (en) 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
KR20060036124A (ko) 1998-03-16 2006-04-27 셀진 코포레이션 염증성 사이토카인 억제제용2-(2,6-디옥소피페리딘-3-일)이소인돌린 유도체, 그제조방법 및 그 용도
JPH11286455A (ja) 1998-03-31 1999-10-19 Kanebo Ltd 骨髄異形成症候群治療薬
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US20030013739A1 (en) 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
GB9904585D0 (en) 1999-02-26 1999-04-21 Gemini Research Limited Clinical and diagnostic database
AU771015B2 (en) 1999-03-18 2004-03-11 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6890547B1 (en) 1999-07-16 2005-05-10 Amato Pharmaceutical Products, Ltd. Glycyrrhizin preparations for transmucosal absorption
US6202923B1 (en) 1999-08-23 2001-03-20 Innovation Associates, Inc. Automated pharmacy
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
US6326388B1 (en) 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
CA2319872C (en) 2000-02-02 2012-06-19 Chun-Ying Huang Pharmaceutical composition for the treatment of hepatocellular carcinoma
AU767812B2 (en) 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
WO2001070275A2 (en) 2000-03-17 2001-09-27 Cell Therapeutics, Inc. Polyglutamic acid-camptothecin conjugates and methods of preparation
AU2001249755A1 (en) 2000-03-31 2001-10-15 Celgene Corporation Inhibition of cyclooxygenase-2 activity
JP5409981B2 (ja) 2000-05-15 2014-02-05 セルジーン コーポレイション 癌治療用の組成物および方法
AU6147301A (en) 2000-05-15 2001-11-26 Celgene Corp Compositions and methods for the treatment of colorectal cancer
WO2002015926A1 (en) 2000-08-24 2002-02-28 Kirin Beer Kabushiki Kaisha c-mpl LIGAND-CONTAINING MEDICINAL COMPOSITIONS FOR INCREASING PLATELETS AND ERYTHROCYTES
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
AU2002253795B2 (en) 2000-11-30 2007-02-01 The Children's Medical Center Corporation Synthesis of 4-Amino-Thalidomide enantiomers
US20020128228A1 (en) 2000-12-01 2002-09-12 Wen-Jen Hwu Compositions and methods for the treatment of cancer
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
ES2338534T3 (es) 2001-02-27 2010-05-10 The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services Analogos de talidomina como inhibidores de la angiogenesis.
CA2457319C (en) 2001-08-06 2011-07-05 The Children's Medical Center Corporation Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
JP4027693B2 (ja) 2002-03-20 2007-12-26 トリニティ工業株式会社 塗料送給装置及びバルブユニット
US20030220254A1 (en) 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
AU2003237078C1 (en) 2002-04-12 2009-10-08 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
NZ536908A (en) 2002-05-17 2008-09-26 Celgene Corp Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
ES2340027T3 (es) 2002-05-17 2010-05-28 Celgene Corporation Combinaciones para tratar el mieloma multiple.
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404717B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US20040162263A1 (en) 2002-10-31 2004-08-19 Supergen, Inc., A Delaware Corporation Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20040152632A1 (en) 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
CL2004001004A1 (es) 2003-05-19 2005-03-18 Upjohn Co Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CA2563207A1 (en) 2004-04-14 2005-11-24 Celgene Corporation Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
US20080199422A1 (en) 2004-04-14 2008-08-21 Celgene Corporation Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20070155791A1 (en) 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
EP2942057A1 (en) * 2006-08-07 2015-11-11 AbbVie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
CA2661983C (en) 2006-08-30 2015-05-05 Mount Sinai School Of Medicine Of New York University Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
JP5388854B2 (ja) 2006-09-26 2014-01-15 セルジーン コーポレイション ５−置換キナゾリノン誘導体、それを含む組成物、及びその使用方法
UA102078C2 (ru) 2007-09-26 2013-06-10 Селджин Корпорэйшн 6-, 7- или 8-замещенные производные хиназолинона и композиция, которая их содержит, и способ их использования
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
EP2211870A1 (en) 2007-11-01 2010-08-04 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
DK3692983T3 (da) 2008-05-15 2021-09-20 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
MX361467B (es) 2008-10-29 2018-12-06 Celgene Corp Compuestos de isoindolina para uso en el tratamiento de cancer.
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
JP5752677B2 (ja) 2009-05-19 2015-07-22 セルジーン コーポレイション ４−アミノ−２−（２，６−ジオキソピペリジン−３−イル）イソインドリン−１，３−ジオンの製剤
SI2536706T1 (sl) 2010-02-11 2017-10-30 Celgene Corporation Derivati arilmetoksi izoindolina in sestavki,ki jih vsebujejo ter metode uporabe le-teh
AU2012229300B2 (en) 2011-03-11 2017-04-20 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
US20140142128A1 (en) 2012-11-20 2014-05-22 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with bruton's tyrosine kinase
CN107249604A (zh) * 2014-12-31 2017-10-13 人类起源公司 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table
BR112017027692A2 (pt) * 2015-06-29 2018-10-09 Bristol Myers Squibb Co regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do câncer

Also Published As

Publication number Publication date
MX2017002382A (es) 2017-05-17
SMT202300081T1 (it) 2023-05-12
LT3182996T (lt) 2023-03-10
ES3043078T3 (en) 2025-11-24
AU2015305449B2 (en) 2021-05-06
PL3182996T3 (pl) 2023-04-17
IL250724A0 (en) 2017-04-30
HRP20230265T1 (hr) 2023-04-14
CA2958867A1 (en) 2016-02-25
SI3182996T1 (sl) 2023-04-28
CN107073115A (zh) 2017-08-18
HUE061382T2 (hu) 2023-06-28
BR112017003620A2 (pt) 2017-12-05
US10034872B2 (en) 2018-07-31
RS64038B1 (sr) 2023-04-28
JP7120763B2 (ja) 2022-08-17
DK3182996T3 (da) 2023-03-13
EP3925609B1 (en) 2025-07-30
MX388383B (es) 2025-03-19
EA201790439A1 (ru) 2017-07-31
JP2021006557A (ja) 2021-01-21
EP3925609A1 (en) 2021-12-22
ES2940302T3 (es) 2023-05-05
AU2021209158A1 (en) 2021-08-19
FI3182996T3 (fi) 2023-03-28
EP3182996B1 (en) 2022-12-28
AU2015305449A1 (en) 2017-03-16
KR20170042598A (ko) 2017-04-19
PT3182996T (pt) 2023-03-21
US20160051530A1 (en) 2016-02-25
WO2016029004A1 (en) 2016-02-25
JP2017525713A (ja) 2017-09-07
EP3182996A1 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
CL2017000416A1 (es) Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
CY1120893T1 (el) Μεθοδοι για αγωγη μολυνσεων ιου filoviridae
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
ECSP17044494A (es) Receptores de antígenos quiméricos de bcma
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CL2018001258A1 (es) Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2
ECSP17073743A (es) Moduladores de k-ras
MX2016013863A (es) Combinacion de lenalidomida y constructo de polipeptido, y sus usos.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
UY37834A (es) Tratamiento de mh con compuestos de pirimidinadiona
MD3360559T2 (ro) Compoziții conținând tulpini bacteriene
CL2015003491A1 (es) Compuestos químicos.
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
GB2541571A (en) Pharmaceutical compositions
MX2016005017A (es) Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
CL2017000792A1 (es) Derivados del ácido borónico
EA201991818A1 (ru) Лечение рака
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
IL283218A (en) Methods of dosing engineered t cells for the treatment of b cell malignancies
EA201790475A1 (ru) Способы лечения системной красной волчанки с использованием доменного антитела против cd28
UY36286A (es) Tratamientos médicos basados en anamorelina
CL2017000152A1 (es) Derivados de isoindolinona
IL292054A (en) Compositions for treatment of abnormal cell growth
MX392383B (es) Metodos para tratar afecciones oculares.